Transplantation in a Disease With a Tp3 Mutation

The phase two trial of a calibrutinib plus lennelitamide plus retuximab or the alr regimen was very interesting. One or three out of ten patients had a tp3 mutation so i'm always looking for other things to do with those patients. perturb root nibs going to see the you know the door is wide open um in these post-car t-cell relapses, he says. The next one is looking at brachi cell so autolusil in the zuma 2 trial and an interesting concept of how do you put the drugs back on the shelf to let them live another day.